Oral misoprostol vs vaginal dinoprostone
It is very uncertain whether oral misoprostol changes oxytocin augmentation compared with vaginal dinoprostone (very low certainty).
- RR 0.9 [0.75, 1.09]12 studies · 9451 participantsVery low
It is very uncertain whether oral misoprostol changes oxytocin augmentation compared with vaginal dinoprostone (very low certainty).
Oral misoprostol may leads to higher oxytocin augmentation compared with vaginal misoprostol (low certainty).
Oral misoprostol may leads to lower oxytocin augmentation compared with mechanical methods (low certainty).
It is very uncertain whether oral misoprostol one‐ to two‐hourly changes oxytocin augmentation compared with oral misoprostol four‐ to six‐hourly (very low certainty).
Oral misoprostol probably leads to lower oxytocin augmentation compared with placebo/no treatment (moderate certainty).
It is very uncertain whether oral misoprostol 20 µg hourly titrated changes oxytocin augmentation compared with oral misoprostol 25 µg two‐hourly static (very low certainty).
Partograph showed no clear difference in oxytocin augmentation compared with no partograph (studies carried out (moderate certainty).
Intravenous showed no clear difference in severe PPH ≥ 1000 mL compared with intramuscular oxytocin (moderate certainty).
Intravenous showed no clear difference in serious maternal morbidity compared with intramuscular oxytocin (moderate certainty).
Intravenous leads to lower PPH ≥ 500 mL compared with intramuscular oxytocin (high certainty).
Intravenous showed no clear difference in use of additional uterotonics compared with intramuscular oxytocin (low certainty).
Intravenous leads to lower blood transfusion compared with intramuscular oxytocin (high certainty).
Intravenous showed no clear difference in hypotension compared with intramuscular oxytocin (moderate certainty).
Oral misoprostol showed no clear difference in vaginal birth within 24 hours compared with intravenous oxytocin (low certainty).
Oral misoprostol probably leads to lower caesarean section compared with intravenous oxytocin (moderate certainty).
It is very uncertain whether oral misoprostol changes uterine hyperstimulation with fetal heart rate changes compared with intravenous oxytocin (very low certainty).
It is very uncertain whether oral misoprostol changes uterine hyperstimulation without fetal heart rate changes compared with intravenous oxytocin (very low certainty).
It is very uncertain whether oral misoprostol changes apgar score less than 7 at 5 minutes compared with intravenous oxytocin (very low certainty).
It is very uncertain whether oral misoprostol changes admission to neonatal intensive care unit compared with intravenous oxytocin (very low certainty).